Receptor News and Research

RSS

Achievements in lupus research, education and advocacy cause for celebration and hope

The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.

23 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Johns Hopkins scientists find a source of nonallergic itch

Scratching below the surface of a troublesome sensation that's equal parts tingle-tickle-prickle, sensory scientists from Johns Hopkins have discovered in mice a molecular basis for nonallergic itch.

23 Dec 2009

Hormone ghrelin influences the consumption of alcohol, study shows

A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Interleukin Genetics introduces the Bone Health Genetic Test

Interleukin Genetics, Inc. announced today availability of the Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

16 Dec 2009

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

UCLA researchers find link between brain cancer and fatty acid synthesis

Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

16 Dec 2009

Receptor News and Research

Achievements in lupus research, education and advocacy cause for celebration and hope

Novel discovery offers hope for patients with common brain tumor

Johns Hopkins scientists find a source of nonallergic itch

Hormone ghrelin influences the consumption of alcohol, study shows

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Clarient announces acquisition of Applied Genomics

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Interleukin Genetics introduces the Bone Health Genetic Test

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

FDA Advisory Committee votes against the approval of Tarceva

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

UCLA researchers find link between brain cancer and fatty acid synthesis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News